A Setback for Alzheimer’s Research?

Jülich, 1 December – Pharmaceutical company Eli Lilly last week completed a major licensing study for a drug against Alzheimer’s – and with disappointing results. It was not possible to prevent or slow down the loss of memory among the patients being treated in the study. Solanezumab, the name of the drug being tested, focuses on amyloid beta proteins as the cause of the disease. This protein also forms the focus of research for Jülich researchers headed by Prof. Dieter Willbold, who explains why the researchers are not in the slightest discouraged by these findings.

More (in German)